Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibody Structure01:10

Antibody Structure

65.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Botulinum neurotoxin Light Chain/A1 uses fast synaptic vesicle cycling to cleave plasma membrane bound SNAP-25.

Communications biology·2025
Same author

Potency Evaluations of Recombinant Botulinum Neurotoxin A1 Mutants Designed to Reduce Toxicity.

International journal of molecular sciences·2024
Same author

Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.

Vaccines·2023
Same author

Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain.

International journal of molecular sciences·2023
Same author

How Botulinum Neurotoxin Light Chain A1 Maintains Stable Association with the Intracellular Neuronal Plasma Membrane.

Toxins·2022
Same author

Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein.

Vaccine·2022
Same journal

Correction for Nishimori et al., “Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis”

Clinical and vaccine immunology : CVI·2018
Same journal

Effect of Breastfeeding and Additional Household Children on Cytomegalovirus Seroprevalence among U.S. Children 1 to 5 Years of Age.

Clinical and vaccine immunology : CVI·2017
Same journal

Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay.

Clinical and vaccine immunology : CVI·2017
Same journal

The Legacy of CVI.

Clinical and vaccine immunology : CVI·2017
Same journal

Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.

Clinical and vaccine immunology : CVI·2017
Same journal

Progress toward Development of a Vaccine against Congenital Cytomegalovirus Infection.

Clinical and vaccine immunology : CVI·2017
See all related articles

Related Experiment Video

Updated: Feb 20, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

45.0K

Protein Structure Facilitates High-Resolution Immunological Mapping.

Madison Zuverink1, Joseph T Barbieri2

  • 1Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Clinical and Vaccine Immunology : CVI
|October 20, 2017
PubMed
Summary
This summary is machine-generated.

Developing next-generation vaccines and therapies against select agents like ricin and botulinum toxin is crucial. Structure-based approaches accelerate the creation of countermeasures for rapid biothreat response.

Keywords:
RTARVEcRiVaxantibodiesbotulinum toxinmass spectrometryricin

More Related Videos

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE
13:28

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

Published on: May 16, 2017

51.0K
Single Particle Cryo-Electron Microscopy: From Sample to Structure
11:52

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Published on: May 29, 2021

9.7K

Related Experiment Videos

Last Updated: Feb 20, 2026

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy
09:37

Optimized Negative Staining: a High-throughput Protocol for Examining Small and Asymmetric Protein Structure by Electron Microscopy

Published on: August 15, 2014

45.0K
High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE
13:28

High-resolution Single Particle Analysis from Electron Cryo-microscopy Images Using SPHIRE

Published on: May 16, 2017

51.0K
Single Particle Cryo-Electron Microscopy: From Sample to Structure
11:52

Single Particle Cryo-Electron Microscopy: From Sample to Structure

Published on: May 29, 2021

9.7K

Area of Science:

  • Biodefense
  • Toxinology
  • Vaccinology

Background:

  • Select agents (SA) present significant regulatory and developmental challenges for medical countermeasures.
  • Toxin-mediated diseases require specific guidelines for SA use, development oversight, and model validation.
  • Existing countermeasures may not be sufficient for emerging biothreats.

Purpose of the Study:

  • To discuss next-generation vaccines and therapies against regulated SA toxins.
  • To highlight the role of structure-based approaches in developing rapid countermeasures.
  • To inform strategies for responding to future biothreats.

Main Methods:

  • Review of current regulatory frameworks for SA countermeasure development.
  • Analysis of structure-based design principles for toxin neutralization.
  • Discussion of advancements in vaccine and therapy development against ricin and botulinum toxin.

Main Results:

  • Structure-based approaches offer a pathway for accelerated development of novel vaccines and therapies.
  • Next-generation countermeasures can be designed to target specific toxin neutralization mechanisms.
  • Regulatory pathways can be adapted to facilitate rapid response to biothreats.

Conclusions:

  • Next-generation vaccines and therapies against SA toxins are essential for biodefense.
  • Structure-based design is a key strategy for rapid development of effective countermeasures.
  • Integrated regulatory and scientific approaches are vital for addressing future biothreats.